Sandimmun neoral pharmacokinetics: impact of the new oral formulation
Holt, D.W.; Mueller, E.A.; Kovarik, J.M.; van Bree, J.B.; Richard, F.; Kutz, K.
Transplantation Proceedings 27(1): 1434-1437
1995
ISSN/ISBN: 0041-1345 PMID: 7878935 Document Number: 453272
Document emailed within 1 workday
Related Documents
Taesch, S.; Niese, D.; Mueller, E.A. 1994: Sandimmun neoral, a new oral formulation of cyclosporin a with improved pharmacokinetic characteristics: safety and tolerability in renal transplant patients Transplantation Proceedings 26(6): 3147-3149Tsang, W.K.; Ho, Y.W.; Tong, K.L.; Chan, W.H.; Chan, A. 1996: Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients Transplantation Proceedings 28(3): 1330-1332
Neumayer, H.H.; Färber, L.; Haller, P.; Kohnen, R.; Maibücher, A.; Schuster, A.; Vollmar, J.; Waiser, J. 1994: Conversion from Sandimmun to Sandimmun Neoral in patients with stable renal allografts: results after 1 month Transplantation Proceedings 26(5): 2944-2948
Soni, S.D.; Tench, D.; Ashwood, T.J.; Movin, G. 1990: Pharmacokinetics of an oral controlled release formulation of remoxipride: a double-blind, crossover comparison with conventional formulation in chronic schizophrenics Acta Psychiatrica Scandinavica. Supplementum 358: 45-47
Min, Z.L.; Zhao, M.; Zhu, Y.H.; Qi, J.; Wang, L.M.; Wang, Y.W. 1996: Experience with clinical use of Sandimmun Neoral in renal transplant patients Transplantation Proceedings 28(3): 1356-1357
Babarykin, D.; Amerika, D.; Adamsone, I.; Valinietse, M.; Rosental, R. 1996: Transfer of patients with kidney grafts to Sandimmun Neoral normalizes the calcium level in erythrocyts Transplantation Proceedings 28(6): 3137
Färber, L.; Maibücher, A.; Geissler, F.; Gutzler, F.; Wiesinger, F.O.; Winkler, M. 1994: Favourable clinical results of Sandimmun-Neoral in malabsorbing liver and heart transplant recipients Transplantation Proceedings 26(5): 2988-2993
Massari, P.U.; Grosso, S.; de Boccardo, G.; Vásquez, M.C.; Schiavelli, R.O.; Sabbatiello, R.R.; Casadei, D.H.; Rial, M.C.; Jost, L.J.; Túrin, M.D.; Agost Carreño C, A.; Maggiora, E.C.; Gadea, M.M. 1996: A randomized, controlled, double-blind study of the safety and tolerability of Sandimmun Neoral in stable renal transplant patients. Argentine Multicentre Study Group Transplantation Proceedings 28(6): 3365-3367
Kuhnz, W.; al-Yacoub, G.; Fuhrmeister, A. 1992: Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation Contraception 46(5): 455-469
Foradori, A.C.; Martínez, L.; Vacarezza, A.; Elberg, L.; Loveluck, A.; Pinto, C. 1994: Pharmacokinetics of a new galenical formulation of oral cyclosporine a in stable kidney transplanted patients Transplantation Proceedings 26(5): 2969-2972
Cainazzo, M.M.; Pinetti, D.; Savino, G.; Bartiromo, M.; Forgione, A.; Bertolini, A. 2005: Pharmacokinetics of a new extended-release nifedipine formulation following a single oral dose, in human volunteers Drugs under Experimental and Clinical Research 31(3): 115-121
Degen, J.; Wölke, E.; Seiberling, M.; Thomann, P.; Völter-Erhardt, H. 1997: Comparison of the relative bioavailability and pharmacokinetics of estrone after oral administration of esterified estrogens in a tablet formulation and an aqueous suspension Arzneimittel-Forschung 47(2): 208-212
Stuart, G.S.; Moses, A.; Corbett, A.; Phiri, G.; Kumwenda, W.; Mkandawire, N.; Chintedze, J.; Malunga, G.; Hosseinipour, M.; Cohen, M.S.; Stanczyk, F.Z.; Kashuba, A.D.M. 2011: Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi Journal of Acquired Immune Deficiency Syndromes 58(2): E40-E43
Dotti, G.; Gaspari, F.; Caruso, R.; Perico, N.; Remuzzi, G.; Barbui, T.; Rambaldi, A. 2001: Pharmacokinetic study of the new cyclosporine-A formulation (Neoral) in adult allogeneic bone marrow transplant recipients Haematologica 86(3): 311-315
Wakasugi, H.; Yoshimoto, M.; Ono, T.; Muso, E.; Inui, K.-i. 2002: Effect of probucol on the blood concentration of cyclosporin a in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral) Nihon Jinzo Gakkai Shi 44(8): 792-797
Vens-Cappell, B.; Hilgenstock, C.; Gellert, M.; Kühle, K.; Reifferscheid, I.; Winckler, P.; Bührens, K.G. 1993: Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration Arzneimittel-Forschung 43(3): 346-350
Diliz, H.S.; Olivera, M.A.; Kershenobich, D.; Mercado, M.A.; Orozco, H. 1996: Change of conventional cyclosporine to neoral cyclosporine formulation in long-term liver transplant recipients Transplantation Proceedings 28(6): 3348-3350
2003: Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects Prescrire International 12(67): 179
Rimal, J.; Shrestha, A. 2015: Validation of Nepalese Oral Health Impact Profile14 and Assessment of its Impact in Patients with Oral Submucous Fibrosis in Nepal Journal of Nepal Health Research Council 13(29): 43-49
Cazzola, M.; Lobefalo, G.; Lupis, F.; Vanacore, L.; Martucci, P.; D'Amato, G. 1989: The effects of cefonicid on the pharmacokinetics of a once-a-day theophylline formulation International Journal of Clinical Pharmacology Research 9(3): 169-173